Drug Profile
Insulin long-acting - Daewoong Pharmaceutical
Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Daewoong Pharmaceutical
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetes mellitus
Most Recent Events
- 30 Apr 2020 Daewoong exercises development and commercialisation licensing option from Affibody for utilising its Albumod™ technology for development of long-acting insulin
- 28 Dec 2019 No recent reports of development identified for research development in Diabetes mellitus in South Korea
- 23 Nov 2015 Early research in Diabetes mellitus in South Korea (Parenteral)